Atorvastatin, a -coenzyme A (HMG-CoA) reductase inhibitor and Ezetimibe is a selective inhibitor of intestinal cholesterol.
Mode of Action:
This is the combination of two medicines: Atorvastatin and Ezetimibe. Atorvastatin is a lipid-lowering medicine, which prevents body from making bad cholesterol LDL by inhibiting HMG-CoA reductase enzyme while raising good cholesterol HDL levels. Ezetimibe is a cholesterol absorption inhibitor, which prevents absorption of cholesterol from the intestines. Together, they provide better reduction of cholesterol in our body.
Primary Hyperlipidemia or Mixed Hyperlipidemia.
Atorvastatin & ezetimibe combination can be taken with or without food. Initial dose: Atorvastatin + ezetimibe 10/10 or 20/10 mg orally once daily. Initial dose for patients who require a larger reduction in LDL-C (greater than 55%): Atorvastatin + ezetimibe 40/10 mg orally once daily.
The risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP3A4_ clarithromycin, HIV protease inhibitors, and litraconazole).
Overdosage: No specific treatment of overdosage with Atorvastatin & Ezetimibe. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as required.
Atorvastatin and Ezetimibe combination is contraindicated in women who are or may become pregnant and also contraindicated in breastfeeding women.
Patients should be advised to report promptly any: Unexplained and/or persistent muscle pain, tenderness, or weakness. Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): Risks increase with higher doses and concomitant use of certain CYP3A4 inhibitors, fibric acid derivatives, and cyclosporine. Predisposing factors include advanced age (>65), uncontrolled hypothyroidism, and renal impairment. Liver enzyme abnormalities: Persistent elevations in hepatic transaminase can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter.
Keep out of reach of children. Store in a dry place, below 30 C temperature and protected from light.